Copy Link Print Information

SB 225002

65 Cited Publications
カスタマーレビュー

Based on 65 publication(s) in Google Scholar

SB225002, a potent, selective and non-peptide CXCR2 antagonist, inhibits 125I-IL-8 binding to CXCR2 with an IC50 of 22 nM.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

  • 純度: 99.90%
  • CAS 番号: 182498-32-4
  • 分子式: C13H10BrN3O4
  • 分子量:352.14
  • 保管条件:

    4°C, stored under nitrogen

    * In solvent : -80°C, 2 years; -20°C, 1 year (stored under nitrogen)

  • SB225002 Chemical Structure
    SB225002 構造式
  • Experimental Validation Results for SB225002
  • Experimental Validation Results for SB225002
  • Experimental Validation Results for SB225002
  • Experimental Validation Results for SB225002
  • Experimental Validation Results for SB225002
CAS 番号: 182498-32-4
容量
価格（税別）
在庫状況
数量
Amount: USD 0.00
Please select quantity
or
or

* アイテムを追加する前、数量をご選択ください

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
最寄りの代理店をお探しください Your local distributor: Hycultec GmbHHycultec
  • 生物活性
  • 化学情報
  • 溶剤 & 溶解度
  • プロトコル
  • 純度とドキュメンテーション
  • 参考文献
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

MedChemExpress（MCE）の使用を引用している文献 SB225002

More
Customer Validation & Images
In Vivo Efficacy StudyFlow CytometryIF
  • In Vivo Efficacy Study
  • In Vivo Efficacy Study
  • Flow Cytometry
  • Flow Cytometry
  • IF

CXCR アイソフォーム固有の製品をすべて表示

More
Keywords
MOQ
Minimum order quantity
100 mg

お問い合わせ 在庫あり

Other size
お問い合わせ
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress ログイン
Register
Sign in to MedChemExpress
新規会員登録

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • SB225002 Chemical Structure
    SB225002 Chemical Structure
    1/16
  • 1/16

    SB225002 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Oct 14;15(1):8845. [Abstract]

    Customer Validation
     SB225002 was administered i.p. at 10 mg/kg after SBRT, and every day for 8 days. Kaplan–Meier survival curves of the efficacy experiment were generated.

  • 1/16

    SB225002 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 Nov;10(33):e2302498. [Abstract]

    Customer Validation
     5 mg/kg SB225002 was administered twice a week alone or in combination by intraperitoneal injection according to the experimental objective. A schematic representation of the therapy schedule for AB680, anti-PD-1 antibody, and CXCR2 inhibitor SB225002 in the KPC orthotopic model was shown. The images of KPC orthotopic allografts from the Control, SB225002, anti-PD-1+AB680, and combination groups were shown.

  • 1/16

    SB225002 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 Nov;10(33):e2302498. [Abstract]

    Customer Validation
     5 mg/kg SB225002 twice a week alone or in combination by intraperitoneal injection according to the experimental objective The percentages of total CD8+ T cells, Granzyme B+ cells among the total CD8+ T cells, and CXCR2+ MDSCs in the tumors of each group at the endpoint were determined by flow cytometry.

  • 1/16

    SB225002 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Nov 26;13(1):7281. [Abstract]

    Customer Validation
     SB225002 (2 mg/kg) in DMSO was diluted in corn oil for in vivo administration through intraperitoneal injection every other day or gavage daily, respectively. Mice were inoculated with WT or Arid1a KO Myc-CaP cells and treated with or without SB225002. Quantification of each tumor-infiltrating immune cell population. was measured by FACS analysis.

  • 1/16

    SB225002 purchased from MedChemExpress. Usage Cited in: J Autoimmun. 2018 May:89:30-40. [Abstract]

    Customer Validation
     The blockade of neutrophil infiltration and intracutaneous injection of exogenous galectin-3 ameliorates skin inflammation in galectin 3-/- mice

  • SB225002